John Olsen, MD

Physician Surveyor for International Healthcare Instiutions.

Lead global Medical Science Liaison (MSL) Matrix throughout China & Emerging Markets. Responsible for more than 300 MSLs and all Sanofi Genzyme product lines in greater than 30 countries across Asia, Latin America, Middle East, Africa, Eurasia and China. * Developed China and Emerging Market dashboard-based field-based medical performance metrics later adopted WorldWide as a universal approach to performance metrics. * Implemented standards and trained 38 country teams to attain higher levels of function and compliance and KOL Engagement. * Initiated the Omni-channel (digital) MSL project to address the increasingly digital landscape of KOL interactions.

Global Vice President, Established Products & Biosurgery. Accountable for Established Products & Biosurgery Medical Affairs strategies and clinical leadership of subject medical expert team responsible for product strategy implementation throughout four global regions. * Initiated internal medical affairs networks that allows improved exchange of knowledge and function along the medical affairs continuum from senior therapy leaders to field teams, content generation to insight development. * Pioneered use of HEOR, modeling, Real World Data (RWD) and Real World Evidence (RWE) in guideline-driven use of therapies.

Regional leadership of Established Products and Biosurgery medical teams throughout the US and Canadian teams. * Stabilized and transitioned North American teams during unexpected leadership changes, and without team attrition. * Developed medical component for country product strategies and targeted country plans. * Primary medical responsibility for fulfilling the US medical commitments under Sanofi's Corporate Integrity Agreement (CIA).

Global Medical Director for Biosurgery, Anesthesia and Critical Care (Surgical Care Franchise) / Therapeutic Area Leader for Anesthesia and Critical Care Product Lines. Developed the medical component of the global business strategy and provided clinical leadership of product strategy implementation regionally. * Revolutionized traditional Global Key Opinion Leaders Seminars and Advisory Boards from product-focus to solution-focus with the practical value of Advisory Boards building solutions for immediate use. * Transitioned the medical affairs team from a classical medical affairs "supporting" role to an enabling and leadership role in clinical trial development, regulatory discussions and product innovation.

Senior Director Role: Developed and Lead the College of American Pathologist's Transformational strategy titled the Case-4-Change. Medical and Scientific Director Role: Senior Physician and Scientist at the College of American Pathologists. * As Senior Director - Built 4 high performing teams comprised of 95 staff and physicians, with annual budget of $10M to develop and implement the Case-4-Change. * As Medical and Science Director - Chartered, developed, implemented and oversaw an innovative and first-ever world-class guideline center focused on pathology and laboratory medicine.

Physician in charge of the global delivery of Drug Safety, Surveillance and Reporting to the Global Regulatory Agencies. * Led traditional drug safety and surveillance teams and committees, numerous task forces and participated in routine and ad hoc regulatory and recall events.